H

HLB Inc
KOSDAQ:028300

Watchlist Manager
HLB Inc
KOSDAQ:028300
Watchlist
Price: 75 400 KRW 2.86% Market Closed
Market Cap: 9.9T KRW
Have any thoughts about
HLB Inc?
Write Note

Operating Margin
HLB Inc

-244.7%
Current
-166%
Average
4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-244.7%
=
Operating Profit
-127.1B
/
Revenue
51.9B

Operating Margin Across Competitors

Country KR
Market Cap 9.9T KRW
Operating Margin
-245%
Country JP
Market Cap 6.8T JPY
Operating Margin
28%
Country CH
Market Cap 37.9B CHF
Operating Margin
13%
Country DK
Market Cap 200.9B DKK
Operating Margin
27%
Country US
Market Cap 16.9B USD
Operating Margin
17%
Country CA
Market Cap 6.9B USD
Operating Margin
4%
Country CN
Market Cap 48.6B CNY
Operating Margin
46%
Country US
Market Cap 6.3B USD
Operating Margin
32%
Country US
Market Cap 6.1B USD
Operating Margin
12%
Country UK
Market Cap 4.8B GBP
Operating Margin
13%
Country CH
Market Cap 4.9B CHF
Operating Margin
14%
No Stocks Found

HLB Inc
Glance View

Market Cap
9.9T KRW
Industry
Health Care

HLB Inc. is a dynamic biopharmaceutical company dedicated to the discovery and development of innovative treatments for a range of serious diseases. Founded on the principles of scientific excellence and a commitment to patient care, HLB has quickly gained recognition for its robust portfolio of drug candidates targeting areas such as oncology, autoimmune diseases, and rare disorders. The company's strategic approach combines cutting-edge research with advanced clinical trials, leveraging partnerships with leading research institutions and healthcare organizations to propel its therapeutic innovations. With a strong financial backing and a clear vision for growth, HLB is not just about developing drugs; it’s about transforming patient outcomes and making a meaningful impact on global health. As an investor, HLB Inc. presents a compelling opportunity anchored in its core strengths: a seasoned management team with a proven track record, a rich pipeline of promising drug candidates, and a robust intellectual property portfolio that secures its market position. The company’s commitment to transparency and strategic operational decisions positions it well for sustainable growth in the competitive biopharmaceutical landscape. With the increasing demand for effective therapies and advancements in medical technology, HLB stands poised to unlock significant shareholder value while driving progress in medical treatment options. This compelling narrative of potential, combined with HLB's dedication to innovation, makes it an intriguing prospect for investors seeking exposure to the biopharmaceutical sector.

Intrinsic Value
880.61 KRW
Overvaluation 99%
Intrinsic Value
Price
H

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-244.7%
=
Operating Profit
-127.1B
/
Revenue
51.9B
What is the Operating Margin of HLB Inc?

Based on HLB Inc's most recent financial statements, the company has Operating Margin of -244.7%.